Skip to main content
Premium Trial:

Request an Annual Quote

HealthLinx’s OvPlex

Premium
HealthLinx, in collaboration with ARL Pathology, this week launched OvPlex, an early-stage test for ovarian cancer detection, in Australia. 
 
OvPlex detects the presence of five protein biomarkers linked to ovarian caner in patient blood samples. HealthLinx claims that its biomarker panel can detect cancer with greater accuracy than the biomarker CA125.
 
In clinical trials, the test yielded 89.2 percent sensitivity and 93.9 percent specificity.
 
The test will be available through general practitioners in Melbourne before being rolled out to other states in Australia. The test will cost $200 and results will be available in 14 days.
 
HealthLinx said in a statement that it is continuing research and development on a next-generation ovarian cancer diagnostic with improved accuracy.

Filed under

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.